Clinical trials
Recruiting Kidney Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
157 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 1 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 2 |
| 2011 | 1 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 6 |
| 2020 | 4 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 19 |
| 2024 | 26 |
| 2025 | 39 |
| 2026 | 23 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 157 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| Memorial Sloan Kettering Cancer Center | 4 |
| Dana-Farber Cancer Institute | 3 |
| Hospices Civils de Lyon | 3 |
| Jinling Hospital, China | 3 |
| Peking University First Hospital | 3 |
| RenJi Hospital | 3 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 3 |
| University Hospital, Bordeaux | 3 |
| A2 Biotherapeutics Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Kidney Neoplasms | 157 |
| Carcinoma, Renal Cell | 61 |
| Prostatic Neoplasms | 30 |
| Lung Neoplasms | 29 |
| Breast Neoplasms | 25 |
| Melanoma | 24 |
| Pancreatic Neoplasms | 23 |
| Urinary Bladder Neoplasms | 23 |
| Neoplasms | 21 |
| Head and Neck Neoplasms | 20 |
Trials
Showing 26 to 50 of 157. Each trial links to its page on Pharma Observatory.
57 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.